Population pharmacokinetic‐pharmacodynamic analyses ...
Lecanemab, a monoclonal antibody targeting Aβ aggregates, shows promise in Alzheimer's disease treatment. PK/PD analyses reveal its effectiveness in reducing amyloid plaques and altering plasma biomarkers (Aβ42/40 ratio, p‐tau181). Biweekly dosing (10 mg/kg) outperforms monthly in efficacy. Post-treatment, amyloid re-accumulation is slow (~4 years), with biomarkers returning to baseline faster. This supports lecanemab's potential in early AD therapy.
Reference News
Lecanemab, a monoclonal antibody targeting Aβ aggregates, shows promise in Alzheimer's disease treatment. PK/PD analyses reveal its effectiveness in reducing amyloid plaques and altering plasma biomarkers (Aβ42/40 ratio, p‐tau181). Biweekly dosing (10 mg/kg) outperforms monthly in efficacy. Post-treatment, amyloid re-accumulation is slow (~4 years), with biomarkers returning to baseline faster. This supports lecanemab's potential in early AD therapy.